Structure elucidation of antiproliferative bisbenzylisoquinoline alkaloids from  Anisocycla grandidieri  from the Madagascar dry forest | Zendy

Liu Yixi | Zendy; Harinantenaina Liva | Zendy; Brodie Peggy J. | Zendy; Slebodnick Carla | Zendy; Callmander Martin W. | Zendy; Rakotondrajaona R. | Zendy; Rakotobe Etienne | Zendy; Rasamison Vincent E. | Zendy; TenDyke Karen | Zendy; Shen Yongchun | Zendy; Kingston David G. I. | Zendy

Premium

Structure elucidation of antiproliferative bisbenzylisoquinoline alkaloids from Anisocycla grandidieri from the Madagascar dry forest

Author(s) -

Liu Yixi,

Harinantenaina Liva,

Brodie Peggy J.,

Slebodnick Carla,

Callmander Martin W.,

Rakotondrajaona R.,

Rakotobe Etienne,

Rasamison Vincent E.,

TenDyke Karen,

Shen Yongchun,

Kingston David G. I.

Publication year - 2013

Publication title -

magnetic resonance in chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.483

H-Index - 72

eISSN - 1097-458X

pISSN - 0749-1581

DOI - 10.1002/mrc.3976

Subject(s) - chemistry , stereochemistry , fractionation , cancer cell lines , cell culture , ethanol , cancer , biochemistry , cancer cell , organic chemistry , medicine , biology , genetics

Antiproliferative bioassay‐guided fractionation of the ethanol extract of the stems of Anisocycla grandidieri led to the isolation of the known alkaloids stebisimine (1), (+)‐1,2‐dehydrotelobine (2), (+)‐2'‐norcocsuline (3) and puetogaline B (4). Herein, we report the full NMR assignments of all compounds and the X‐ray crystallography of single crystals of compounds 1 and 3. Compounds 2 and 3 showed moderate antiproliferative activity against the A2780 human ovarian cancer cell line with IC 50 values of 4.1 ± 0.3 and 2.7 ± 0.3 μM, respectively, and they also displayed selective activity toward the H460 (large cell lung cancer), MCF‐7 (breast ductal carcinoma), and UACC‐257 (melanoma) cell lines. Copyright © 2013 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research